Introduction {#sec1}
============

lncRNAs are noncoding RNAs longer than 200 bp without apparent protein-coding potential; they can function as oncogenes or suppressor genes in the process of carcinogenesis \[[@B1]\]. At lncRNA loci, genetic variation can occur, which contributes to a change of lncRNA function. Single-nucleotide polymorphisms (SNPs) are the most common pattern of genetic variation. As reported previously, SNPs have the potential to act as biomarkers for cancer susceptibility \[[@B2],[@B3]\]. Some lncRNA polymorphisms were considered to be predictive of cancer risk, to be useful for early diagnosis, and to aid in the management of personalized therapy \[[@B2],[@B4]\].

The expression patterns of prostate cancer-associated transcripts (PCATs) distinguish benign localized cancer and metastatic cancer samples. In 2012, Prensner et al. \[[@B5]\] reported the discovery of a novel prostate cancer lncRNA, PCAT-1, which alternately demonstrates either repression by PRC2 or an active role in promoting cell proliferation through transcriptional regulation of target genes. Subsequently, Ge et al. \[[@B6]\] identified the up-regulation of PCAT1 expression in colorectal cancer (CRC) tissues, indicating that PCAT1 functions as an oncogene in CRC. Concerning *PCAT1* SNPs, only one investigation has reported their association with cancer susceptibility, which found that *PCAT1* rs1902432 tagSNP was associated with prostate cancer risk \[[@B7]\]. However, no comprehensive analysis of the association of all tagSNPs of *PCAT1* with cancer susceptibility has yet been performed, including for CRC.

In the present study, we thus performed a study to investigate the association between the tagSNPs of the *PCAT1* gene and CRC susceptibility. The present study sought biomarkers predictive of CRC risk and was intended to unearth clues providing a deeper understanding of the etiology of colorectal carcinogenesis.

Materials and methods {#sec2}
=====================

Patients {#sec2-1}
--------

This research project was approved by the institutional review board of First Affiliated Hospital of China Medical University. All the participants are according to the principles expressed in the Declaration of Helsinki. A total of 436 CRC patients, who had undergone a surgical operation for CRC at the Shengjing Affiliated Hospital of China Medical University, were consecutively recruited between 2016 and 2017. The presnt study is retrospective and designed as a case-control study. In all of these subjects, the pathological diagnosis was confirmed based on the AJCC classification. According to the site of occurrence, there were 229 colon cancer patients and 207 rectal cancer patients. A total of 510 controls were also recruited from a health check program at the same hospital. And the inclusion and exclusion criteria for the case and control groups were: 1) the race is consistent and are all Asian; 2) the pathological diagnosis is definite clear in case group; 3) the healthy controls have the normal serum biochemical indexes and excluded all other systemic diseases; 4) multiple tumor patients with prostate cancer or bladder cancer or cervical cancer were excluded; and 5) patients who received preoperative radiotherapy or chemotherapy were excluded.

Written informed consent was provided by each individual, and the medical records were used for the pathological diagnosis and TNM staging of the CRC cases. A questionnaire was used to collect information on the smoking, drinking, and family history of the cases. The smoking and drinking information are defined by referring the previously published study \[[@B8]\]: cigarette smoker was defined as who have smoked at least 100 cigarettes during one's lifetime or had been smoking any amount for at least 1 year, which included current smokers and former smokers. Alcohol drinker was defined as who consumed one or more alcoholic drinks per week for \>1 year. One drink equals to one 12-oz can or bottle of beer (5% ethanol), one 5-oz glass of wine (12.5% ethanol), or 1.5-oz measure of liquor (40% ethanol) for each subject.

Whole blood from individuals was collected and blood clots were allowed to form by incubating clot-activating tubes at room temperature for 1 h. Each clot was transferred to a 2-ml centrifuge tube and stored at −80°C until DNA extraction.

Polymorphisms selected and SNP Genotyping {#sec2-2}
-----------------------------------------

The polymorphisms selected method was based on our previously published study \[[@B9]\]. The linkage disequilibrium (LD) of *PCAT1* gene was shown in Supplementary Figure 1. Then five SNPs covered *PCAT1* gene (rs1902432, rs4573233, rs710885, rs785005, rs2632159) were selected \[[@B8],[@B10]\], other SNPs captured by the selected ones were shown in Supplementary Table S1. Genomic DNA was purified from the blood as described previously \[[@B13]\], with some modifications, and was diluted to working concentrations of 50 ng/l for the *PCAT1* polymorphism genotyping. Polymorphisms-genotyping assay was performed using Kompetitive Allele-Specific PCR (KASP, LGC Genomics, Hoddesdon, U.K.) by Gene Company (Shanghai, China) \[[@B14],[@B15]\] and 10% of the total samples were repeatedly genotyped at the same time for quality control (the concordance rate all reached 100%).

eQTLs {#sec2-3}
-----

To perform the promising functional polymorphism of *PCAT1* gene and expression quantitative trait locus (eQTL) analysis, we used the bioinformatical online software Haploreg (<http://www.broadinstitute.org/mammals/haploreg/haploreg.php>) \[[@B16]\] to mine the data.

Statistical analysis {#sec2-4}
--------------------

In the present study, all analyses were conducted on the CRC risk, colon cancer risk, and rectal cancer risk. The association between lncRNA-*PCAT1* gene polymorphisms and CRC risk was determined using multivariate logistic regression adjusted for age and gender. The lncRNA haplotype was analyzed using the online software SHEsis \[[@B17]\]. The epistatic effects of pairwise interacting factors for the polymorphism of the *PCAT1* gene (rs2632159) with the strongest potential effect and other SNPs on the risk of CRC were analyzed by multivariate logistic regression adjusted for age and gender. The association between the genotype of *PCAT1* SNPs and clinicopathological parameters was calculated using χ^2^ two-sided test.

Results {#sec3}
=======

The association of lncRNA-PCAT1 SNPs with CRC susceptibility {#sec3-1}
------------------------------------------------------------

In the present study, the *PCAT1* rs2632159 polymorphism was found to increase CRC risk by 1.37-fold and 2.19-fold in the dominant and recessive models, respectively (*P*=0.040 and 0.041). When the CRC cases were divided into colon cancer and rectal cancer, we found that *PCAT1* rs2632159 was associated with colon cancer risk under the dominant model (*P*=0.022, OR = 1.51) and with rectal cancer susceptibility under the recessive model (*P*=0.009, OR = 3.03). In addition, *PCAT1* rs1902432 polymorphism decreased colon cancer risk to 0.59-fold (*P*=0.030, [Table 1](#T1){ref-type="table"}).

###### The association of *PCAT1* polymorphisms and CRC risk

  SNP^\*^     Genotype      *P*~HWE~   Controls (%)   CRC           CRC vs CON    Colon cancer vs CON   Rectal cancer vs CON                                                                           
  ----------- ------------- ---------- -------------- ------------- ------------- --------------------- ---------------------- ----------------------- ----------- ----------------------- ----------- -----------------------
  rs1902432   TT            0.557      170 (34.07)    160 (36.87)   90 (39.47)    70 (33.98)                                                                       1 (Ref)                             1 (Ref)
              TC                       237 (47.49)    208 (47.92)   111 (48.68)   97 (47.09)            0.830                  0.97 (0.71--1.31)       0.638       0.92 (0.64--1.31)       0.874       1.03 (0.71--1.51)
              CC                       92 (18.44)     66 (15.21)    27 (11.85)    39 (18.93)            0.163                  0.74 (0.49--1.13)       **0.030**   **0.57 (0.33--0.94)**   0.916       0.97 (0.59--1.60)
              CC+TC vs TT                                                                               0.519                  0.91 (0.6--1.22)        0.252       0.82 (0.58--1.15)       0.893       1.03 (0.72--1.47)
              CC vs TT+TC                                                                               0.158                  0.76 (0.53--1.11)       **0.030**   **0.59 (0.36--0.95)**   0.897       0.97 (0.63--1.51)
              C vs T                                                                                    0.229                  0.89 (0.73--1.08)       0.051       0.79 (0.62--1.00)       0.970       1.01 (0.79--1.28)
  rs4573233   GG            0.688      331 (66.73)    274 (63.57)   141 (61.84)   133 (65.52)                                                                      1 (Ref)                             1 (Ref)
              GA                       150 (30.24)    138 (32.02)   77 (33.77)    61 (30.05)            0.615                  1.08 (0.80--1.47)       0.394       1.17 (0.82--1.67)       0.947       0.99 (0.68--1.44)
              AA                       15 (3.03)      19 (4.41)     10 (4.39)     9 (4.93)              0.273                  1.54 (0.71--3.32)       0.333       1.55 (0.64--3.76)       0.365       1.53 (0.61--3.80)
              AA+GA vs GG                                                                               0.442                  1.12 (0.84--1.50)       0.297       1.20 (0.85--1.69)       0.850       1.04 (0.72--1.49)
              AA vs GG+GA                                                                               0.294                  1.50 (0.71--3.18)       0.400       1.46 (0.61--3.48)       0.344       1.54 (0.63--3.78)
              A vs G                                                                                    0.312                  1.14 (0.89--1.46)       0.243       1.19 (0.89--1.60)       0.631       1.08 (0.79--1.47)
  rs710885    TT            0.122      446 (88.32)    370 (85.65)   195 (85.53)   175 (85.78)                                                                      1 (Ref)                             1 (Ref)
              TG                       55 (10.89)     57 (13.19)    32 (14.04)    25 (12.25)            0.090                  1.45 (0.94--2.21)       0.100       1.51 (0.92--2.48)       0.250       1.37 (0.80--2.32)
              GG                       4 (0.79)       5 (1.16)      1 (0.43)      4 (1.97)              0.506                  1.62 (0.39--6.76)       0.673       0.62 (0.06--5.88)       0.176       2.84 (0.63--12.93)
              GG+TG vs TT                                                                               0.072                  1.46 (0.97--2.21)       0.133       1.45 (0.89--2.35)       0.132       1.48 (0.89--2.45)
              GG vs TT+TG                                                                               0.543                  1.56 (0.37--6.54)       0.647       0.59 (0.06--5.65)       0.193       2.74 (0.60--12.51)
              G vs T                                                                                    0.065                  1.44 (0.98--2.11)       0.192       1.35 (0.86--2.14)       0.071       1.53 (0.96--2.44)
  rs785005    GG            0.629      221 (44.92)    199 (45.96)   97 (42.73)    102 (49.51)                                                                      1 (Ref)                             1 (Ref)
              GA                       221 (44.92)    190 (43.88)   102 (44.94)   88 (42.72)            0.579                  0.92 (0.68--1.24)       0.982       1.00 (0.70--1.43)       0.334       0.84 (0.58--1.20)
              AA                       50 (10.16)     44 (10.16)    28 (12.33)    16 (7.77)             0.763                  0.93 (0.57--1.52)       0.509       1.21 (0.69--2.11)       0.198       0.65 (0.34--1.25)
              AA+GA vs GG                                                                               0.570                  0.92 (0.70--1.22)       0.808       1.04 (0.75--1.46)       0.216       0.80 (0.57--1.14)
              AA vs GG+GA                                                                               0.896                  0.97 (0.61--1.54)       0.474       1.21 (0.71--2.04)       0.292       0.72 (0.39--1.33)
              A vs G                                                                                    0.627                  0.95 (0.77--1.17)       0.607       1.07 (0.83--1.37)       0.159       0.83 (0.64--1.08)
  rs2632159   TT            0.991      357 (70.55)    281 (65.20)   142 (62.83)   139 (67.81)                                                                      1 (Ref)                             1 (Ref)
              TC                       136 (26.88)    130 (30.16)   77 (34.07)    53 (25.85)            0.129                  1.27 (0.93--1.73)       **0.033**   **1.48 (1.03--2.12)**   0.789       1.06 (0.71--1.56)
              CC                       13 (2.57)      20 (4.64)     7 (3.10)      13 (6.34)             **0.026**              **2.38 (1.11--5.09)**   0.304       1.67 (0.63--4.41)       **0.008**   **3.12 (1.34--7.23)**
              CC+TC vs TT                                                                               **0.040**              **1.37 (1.01--1.84)**   **0.022**   **1.51 (1.06--2.14)**   0.286       1.22 (0.85--1.77)
              CC vs TT+TC                                                                               **0.041**              **2.19 (1.03--4.64)**   0.445       1.46 (0.56--3.81)       **0.009**   **3.03 (1.32--6.94)**
              C vs T                                                                                    **0.013**              **1.39 (1.07--1.79)**   **0.023**   **1.42 (1.05--1.92)**   0.061       1.35 (0.99--1.85)

Terms in bold represent significant results (*P*\<0.05). *P*~HWE~ = *P* value for Hardy--Weinberg Equilibrium.Abbreviations: CRC, colorectal cancer; NA, not available. ^\*^, the sort order was according to the SNP location in its genes from 5′ starting to 3′ ends. ^†^, *P* value was calculated by adjusted age and gender.

Subgroup analysis {#sec3-2}
-----------------

In the male subgroup, *PCAT1* rs2632159 SNP also increased rectal cancer risk by 3.97-fold in the male subgroup (*P*=0.017, [Table 2](#T2){ref-type="table"}), while *PCAT1* rs710885 polymorphism increased CRC risk by 2.09-fold and colon cancer risk by 2.60-fold (*P* = 0.033, *P* = 0.013, [Table 2](#T2){ref-type="table"}).

###### Association of lnRNA-*PCAT1* polymorphisms with the CRC susceptibility stratified by host characteristics

  SNP         Variable   Genotype   CON   CRC   CRC vs CON   Colon cancer vs CON   Rectal cancer vs CON                                                                           
  ----------- ---------- ---------- ----- ----- ------------ --------------------- ---------------------- ----------------------- ----------- ----------------------- ----------- ------------------------
  rs1902432   Gender                                                                                                                                                              
                Male     TT         77    90    44           46                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TC         106   113   56           57                    0.733                  0.93 (0.59--1.45)       0.813       0.94 (0.55--1.59)       0.733       0.91 (0.54--1.54)
                         CC         45    47    19           28                    0.558                  0.85 (0.48--1.49)       0.311       0.70 (0.35--1.40)       0.961       0.98 (0.52--1.87)
                Female   TT         93    70    46           24                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TC         131   95    55           40                    0.973                  0.99 (0.65--1.51)       0.608       0.88 (0.54--1.43)       0.531       1.20 (0.68--2.14)
                         CC         47    19    8            11                    0.109                  0.59 (0.31--1.13)       0.028       0.38 (0.16--0.90)       0.908       0.95 (0.43--2.14)
              Age                                                                                                                                                                 
                ≦60      TT         120   80    40           40                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TC         173   106   59           47                    0.679                  0.92 (0.64--1.34)       0.925       1.02 (0.64--1.63)       0.436       0.83 (0.51--1.34)
                         CC         75    32    14           18                    0.073                  0.63 (0.38--1.04)       0.088       0.56 (0.28--1.09)       0.279       0.71 (0.38--1.33)
                \>60     TT         50    80    50           30                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TC         64    102   52           50                    0.830                  0.95 (0.58--1.54)       0.399       0.79 (0.46--1.36)       0.495       1.24 (0.67--2.26)
                         CC         17    34    13           21                    0.867                  1.06 (0.52--2.15)       0.388       0.69 (0.30--1.60)       0.206       1.70 (0.75--3.84)
  rs4573233   Gender                                                                                                                                                              
                Male     GG         152   160   77           83                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         GA         66    79    37           42                    0.815                  1.06 (0.67--1.65)       0.933       1.02 (0.60--1.75)       0.759       1.08 (0.65--1.82)
                         AA         5     11    5            6                     0.090                  2.90 (0.85--9.93)       0.162       2.69 (0.67--10.73)      0.102       3.14 (0.80--12.33)
                Female   GG         10    8     64           50                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         GA         84    59    40           19                    0.659                  1.10 (0.72--1.67)       0.248       1.33 (0.82--2.16)       0.485       0.81 (0.45--1.47)
                         AA         179   114   5            3                     0.890                  1.07 (0.39--2.96)       0.818       1.15 (0.35--3.72)       0.961       0.97 (0.25--3.75)
              Age                                                                                                                                                                 
                ≦60      GG         254   142   75           67                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         GA         104   67    35           32                    0.450                  1.15 (0.80--1.67)       0.579       1.14 (0.72--1.81)       0.525       1.17 (0.72--1.89)
                         AA         10    7     3            4                     0.659                  1.25 (0.47--3.35)       0.985       1.01 (0.27--3.78)       0.495       1.51 (0.46--4.98)
                \>60     GG         77    132   66           66                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         GA         46    71    42           29                    0.749                  0.92 (0.57--1.50)       0.792       1.08 (0.63--1.85)       0.343       0.75 (0.41--1.36)
                         AA         5     12    7            5                     0.352                  1.71 (0.55--5.28)       0.315       1.87 (0.55--6.32)       0.561       1.50 (0.39--5.81)
  rs710885    Gender                                                                                                                                                              
                Male     TT         210   217   102          115                                          1 (Ref)                             1 (Ref)                             1 (Ref)
                         TG         19    31    18           13                    **0.033**              **2.09 (1.06--4.11)**   **0.013**   **2.60 (1.22--5.55)**   0.222       1.65 (0.74--3.68)
                         GG         1     3     0            3                     0.506                  2.20 (0.22--22.60)      NA          NA                      0.233       4.12 (0.40--42.27)
                Female   TT         236   153   93           60                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TG         36    26    14           12                    0.657                  1.14 (0.65--1.99)       0.985       1.01 (0.51--.99)        0.438       1.33 (0.65--2.74)
                         GG         3     2     1            1                     0.862                  1.18 (0.18--7.62)       0.986       0.98 (0.10--10.10)      0.741       1.48 (0.15--15.10)
              Age                                                                                                                                                                 
                ≦60      TT         327   181   95           86                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TG         40    33    18           15                    0.106                  1.51 (0.92--2.47)       0.152       1.55 (0.85--2.84)       0.254       1.45 (0.77--2.76)
                         GG         4     1     0            1                     0.491                  0.46 (0.05--4.17)       NA          NA                      0.997       1.01 (0.11--9.20)
                \>60     TT         119   189   100          89                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TG         15    24    14           10                    0.677                  1.16 (0.57--2.37)       0.607       1.23 (0.56--2.71)       0.878       1.07 (0.44--2.60)
                         GG         0     4     1            3                     NA                     NA                      NA          NA                      NA          NA
  rs785005    Gender                                                                                                                                                              
                Male     GG         99    121   53           68                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         GA         96    107   54           53                    0.528                  0.87 (0.56--1.35)       0.997       1.00 (0.60--1.68)       0.298       0.77 (0.46--1.27)
                         AA         28    24    13           11                    0.395                  0.73 (0.35--1.51)       0.824       0.91 (0.39--2.12)       0.240       0.60 (0.26--1.41)
                Female   GG         122   78    44           34                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         GA         125   83    48           35                    0.936                  0.98 (0.65--1.48)       0.989       1.00 (0.61--1.64)       0.876       0.96 (0.56--1.65)
                         AA         22    20    15           5                     0.458                  1.30 (0.65--2.59)       0.157       1.73 (0.81--3.70)       0.576       0.74 (0.26--2.14)
              Age                                                                                                                                                                 
                ≦60      GG         169   96    48           48                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         GA         160   98    51           47                    0.655                  1.09 (0.76--1.55)       0.607       1.13 (0.72--1.76)       0.855       1.04 (0.66--1.65)
                         AA         52    103   14           10                    0.709                  1.12 (0.63--1.97)       0.413       1.34 (0.67--2.68)       0.794       0.90 (0.42--1.95)
                \>60     GG         52    103   49           54                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         GA         61    92    51           41                    0.320                  0.78 (0.48--1.27)       0.706       0.90 (0.52--1.56)       0.160       0.66 (0.37--1.18)
                         AA         12    20    14           6                     0.880                  094 (0.40--2.20)        0.552       1.32 (0.53--3.27)       0.259       0.53 (0.17--1.61)
  rs2632159   Gender                                                                                                                                                              
                Male     TT         169   166   75           91                                           1 (Ref)                                                                 
                         TC         56    71    41           30                    0.396                  1.22 (0.77--1.94)       0.100       1.56 (0.92--2.65)       0.829       0.94 (0.54--1.64)
                         CC         6     12    2            10                    0.081                  2.64 (0.89--7.82)       0.978       0.98 (0.18--5.23)       **0.017**   **3.97 (1.28--12.25)**
                Female   TT         188   115   67           48                                           1 (Ref)                                                                 
                         TC         80    59    36           23                    0.269                  1.27 (0.83--1.93)       0.250       1.34 (0.82--2.20)       0.580       1.17 (0.67--2.07)
                         CC         7     8     5            3                     0.164                  2.14 (0.73--6.23)       0.167       2.35 (0.70--7.92)       0.385       1.86 (0.46--7.61)
              Age                                                                                                                                                                 
                ≦60      TT         262   140   71           69                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TC         97    65    37           28                    0.185                  1.73 (0.77--3.90)       0.139       1.42 (0.89--2.25)       0.679       1.11 (0.68--1.83)
                         CC         13    12    5            7                     0.218                  1.27 (0.87--1.84)       0.522       1.42 (0.49--4.11)       0.140       2.06 (0.79--5.39)
                \>60     TT         95    141   71           70                                           1 (Ref)                             1 (Ref)                             1 (Ref)
                         TC         39    65    40           25                    NA                     NA                      0.240       1.39 (0.80--2.40)       0.706       0.89 (0.48--1.65)
                         CC         0     8     2            6                     0.563                  1.16 (0.71--1.89)       NA          NA                      NA          NA

Terms in bold represent significant results (*P*\<0.05).

^\*^using Logistic Regression adjusted by the two factors of gender and age. Abbreviations: CON, controls; CRC, colorectal cancer. NA, not available.

Haplotype analysis {#sec3-3}
------------------

In the haplotype analysis, no haplotype of the *PCAT1* gene had any association with CRC risk (haplotype for rs1902432-rs4573233-rs710885-rs785005-rs2632159 SNPs, *P*\>0.05). However, when cases were divided into colon cancer and rectal cancer, the *PCAT1* gene C-G-T-G-T haplotype decreased colon cancer risk to 0.75-fold (*P*=0.019, [Table 3](#T3){ref-type="table"}).

###### The association of haplotype of *PCAT1* gene and CRC risk

  Haplotype   Control (%)     CRC             CRC vs CON      Colon cancer vs CON   Rectal cancer vs CON                                                                   
  ----------- --------------- --------------- --------------- --------------------- ---------------------- ------------------- ----------- ----------------------- ------- -------------------
  C G T G T   395.24 (41.6)   326.83 (39.0)   154.44 (34.9)   171.99 (43.4)         0.238                  0.89 (0.74--1.08)   **0.019**   **0.75 (0.60--0.95)**   0.615   1.06 (0.84--1.35)
  T A T G C   85.64 (9.0)     91.75 (10.9)    50.77 (11.5)    41.79 (10.6)          0.178                  1.24 (0.91--1.69)   0.145       1.31 (0.91--1.90)       0.405   1.18 (0.80--1.74)
  T A T G T   88.36 (9.3)     76.25 (9.1)     41.23 (9.3)     34.21 (8.6)           0.866                  0.97 (0.71--1.34)   0.979       1.01 (0.68--1.48)       0.669   0.91 (0.60--1.38)
  T G G G C   56.52 (5.9)     64.70 (7.7)     31.64 (7.2)     33.00 (8.3)           0.142                  1.32 (0.91--1.91)   0.384       1.22 (0.78--1.92)       0.119   1.43 (0.91--2.23)
  T G T A T   308.92 (32.5)   267.57 (31.9)   155.98 (35.3)   111.85 (28.2)         0.755                  0.97 (0.79--1.18)   0.294       1.14 (0.90--1.44)       0.102   0.81 (0.62--1.04)

The bold terms means the significant results (*P*\<0.05). Using SHEsis software to analysis (<http://analysis.bio-x.cn/>). The haplotype for rs1902432 -- rs4573233 -rs710885 -- rs785005 -- rs2632159 SNPs. CRC: colorectal cancer.

Epistatic effect analysis {#sec3-4}
-------------------------

To mine the associations of the SNPs with positive results, rs2632159, and other SNPs with the risk of CRC, the epistatic effects of rs2632159 interacting with four other SNPs were calculated. When there is rs2632159 polymorphism, the rs1902432 TT+TC variant genotype was shown to increase rectal cancer risk 2.93-fold (*P*=0.011, 95% CI = 1.28--6.70), and the rs785005 GG variant genotype increased colon cancer risk 2.01-fold (*P*=0.008, 95% CI = 1.21--3.28, [Table 4](#T4){ref-type="table"}).

###### Epistatic effect of pairwise interacting factors for *PCAT1* on the risks of CRC

  Interacted pairwise SNPs              Comparison              Subset            CRC vs CON   Colon cancer vs CON   Rectal cancer vs CON                                       
  ------------------------------------- ----------------------- ----------------- ------------ --------------------- ---------------------- ----------------------- ----------- -----------------------
  rs1902432 interacted with rs2632159   rs1902432 CC vs TT+TC   rs2632159 CC      NA           NA                    NA                     NA                      NA          NA
                                                                rs2632159 TT+TC   0.196        0.78 (0.54--1.14)     0.025                  0.57 (0.35--0.93)       0.871       1.04 (0.67--1.62)
                                        rs2632159 CC vs TT+TC   rs1902432 CC      NA           NA                    NA                     NA                      NA          NA
                                                                rs1902432 TT+TC   0.065        2.02 (0.96--4.27)     0.603                  1.29 (0.49--3.37)       **0.011**   **2.93 (1.28--6.70)**
  rs4573233 interacted with rs2632159   rs4573233 AA+GA vs GG   rs2632159 CC      0.547        0.85 (0.51--1.44)     NA                     NA                      NA          NA
                                                                rs2632159 TT+TC   0.788        1.06 (0.70--1.61)     0.441                  1.15 (0.81--1.64)       0.820       0.96 (0.67--1.40)
                                        rs2632159 CC vs TT+TC   rs4573233 AA+GA   0.406        1.23 (0.76--1.98)     0.200                  1.45 (0.82--2.57)       0.991       1.00 (0.55--1.83)
                                                                rs4573233 GG      0.063        1.55 (0.98--2.45)     0.101                  1.57 (0.92--2.69)       0.141       1.52 (0.87--2.66)
  rs710885 interacted with rs2632159    rs710885 GG+TG vs TT    rs2632159 CC      0.266        1.34 (0.80--2.23)     0.310                  0.16 (0.01--5.49)       0.195       0.11 (0.00--3.09)
                                                                rs2632159 TT+TC   0.570        0.58 (0.09--3.77)     0.164                  1.45 (0.86--2.44)       0.310       1.34 (0.76--2.34)
                                        rs2632159 CC vs TT+TC   rs710885 GG+TG    0.189        3.84 (0.52--28.60)    0.516                  1.95 (0.26--14.50)      NA          NA
                                                                rs710885 TT       0.321        1.20 (0.84--1.72)     0.109                  1.40 (0.93--2.13)       0.959       0.99 (0.62--1.56)
  rs785005 interacted with rs2632159    rs785005 AA+GA vs GG    rs2632159 CC      0.672        0.89 (0.53--1.51)     NA                     NA                      NA          NA
                                                                rs2632159 TT+TC   0.643        1.09 (0.76--1.55)     0.496                  1.13 (0.80--1.59)       0.425       0.87 (0.61--1.23)
                                        rs2632159 CC vs TT+TC   rs785005 AA+GA    0.390        1.22 (0.77--1.94)     0.388                  1.27 (0.74--2.16)       0.590       1.17 (0.66--2.10)
                                                                rs785005 GG       0.051        1.55 (1.00--2.40)     **0.008**              **2.01 (1.21--3.28)**   0.540       1.18 (0.70--1.98)

Terms in bold represent significant results (*P*\<0.05). All tests were adjusted by age and gender. Statistically significant associations were highlighted in bold (*P*\<0.05). Abbreviations: CON, controls; CRC, colorectal cancer.

Association of SNPs and clinical pathological parameters {#sec3-5}
--------------------------------------------------------

We mined the distribution frequencies of five SNPs in association with different clinical pathological parameters and found in all CRC patients that the frequency of genotypes with the rs785005 SNP variant was higher in the cases with high/moderate-differentiation adenocarcinoma (variant genotype vs heterozygote/wild-type genotype: 97.5% vs 83.0%/81.5%, [Table 5](#T5){ref-type="table"}). Meanwhile, in colon cancer patients, the frequency of rs4573233 SNP variant genotype was higher in poor-differentiation adenocarcinoma (variant genotype vs heterozygote/wild-type genotype: 62.5% vs 83.3%/86.2%, [Table 5](#T5){ref-type="table"}). Moreover, the frequency of the rs2632159 SNP variant genotype was higher in the never smokers (variant genotype vs heterozygote/wild-type genotype: 100.0% vs 61.0%/64.1%, [Table 5](#T5){ref-type="table"}).

###### The association between the genotype of *PCAT1* SNPs and clinicopathological parameters^\*^

  Parameter                         *n*           Genotype for CRC   *P* value    Genotype for Colon cancer   *P* value   Genotype for Rectal cancer   *P* value                                                                  
  --------------------------------- ------------- ------------------ ------------ --------------------------- ----------- ---------------------------- ------------ ------------ ----------- ------------ ----------- ----------- -------
  rs1902432                                                                                                                                                                                                                       
  Smoking                                                                                                     0.068                                                              0.130                                            0.392
    Ever smoker                     173 (39.86)   64 (40.0)          76 (36.5)    33 (50.0)                               30 (33.3)                    37 (33.3)    13 (48.1)                34 (48.6)    39 (40.2)   20 (51.3)   
    Never smoker                    261 (60.14)   96 (60.0)          132 (63.5)   33 (50.0)                               60 (66.7)                    74 (66.7)    14 (51.9)                36 (51.4)    58 (59.8)   19 (48.7)   
  Drinking                                                                                                    0.765                                                              0.439                                            0.763
    Drinker                         48 (11.06)    20 (12.5)          20 (9.6)     8 (12.1)                                9 (10.0)                     11 (9.9)     4 (14.8)                 11 (15.7)    9 (9.3)     4 (10.3)    
    Nondrinker                      386 (88.94)   140 (87.5)         188 (90.4)   58 (87.9)                               81 (90.0)                    100 (90.1)   23 (85.2)                59 (84.3)    88 (90.7)   35 (89.7)   
  Family history                                                                                              0.207                                                              0.772                                            0.097
    Yes                             25 (5.76)     8 (5.0)            11 (5.3)     6 (9.1)                                 6 (6.7)                      4 (3.6)      1 (3.7)                  2 (2.9)      7 (7.2)     5 (12.8)    
    No                              409 (94.24)   152 (95.0)         197 (94.7)   60 (90.9)                               84 (93.3)                    107 (96.4)   26 (96.3)                68 (97.1)    90 (92.8)   34 (87.2)   
  WHO classification                                                                                          0.603                                                              0.052                                            0.664
    High-moderate differentiation   322 (83.64)   123 (86.6)         149 (82.3)   50 (80.6)                               71 (87.7)                    81 (83.5)    20 (76.9)                52 (85.2)    68 (81.0)   30 (83.3)   
    Poor differentiation            21 (5.45)     6 (4.2)            10 (5.5)     5 (8.1)                                 2 (2.5)                      5 (5.2)      4 (15.4)                 4 (6.6)      5 (6.0)     1 (2.8)     
    Mucinous adenocarcinoma         42 (10.91)    13 (9.2)           22 (12.2)    7 (11.3)                                8 (9.9)                      11 (11.3)    2 (7.7)                  5 (8.2)      11 (13.1)   5 (13.9)    
  TNM stage                                                                                                   0.506                                                              0.185                                            0.690
    I--II                           174 (40.65)   64 (40.0)          86 (42.4)    24 (36.9)                               35 (38.9)                    53 (49.1)    8 (30.8)                 29 (41.4)    33 (34.7)   16 (41.0)   
    III--IV                         254 (59.35)   96 (60.0)          117 (57.8)   41 (63.1)                               55 (61.1)                    55 (50.9)    18 (69.2)                41 (58.6)    62 (65.3)   23 (59.0)   
  rs4573233                                                                                                                                                                                                                       
  Smoking                                                                                                     0.858                                                              0.730                                            0.548
    Ever smoker                     173 (40.14)   108 (39.4)         57 (41.3)    8 (42.1)                                51 (36.2)                    26 (33.8)    3 (30.0)                 57 (42.9)    31 (50.8)   5 (55.6)    
    Never smoker                    258 (59.86)   166 (60.6)         81 (58.7)    11 (57.9)                               90 (63.8)                    51 (66.2)    7 (70.0)                 76 (57.1)    30 (49.2)   4 (44.4)    
  Drinking                                                                                                    0.931                                                              0.267                                            0.323
    Drinker                         48 (11.14)    29 (10.6)          17 (12.3)    2 (10.5)                                16 (11.3)                    8 (10.4)     0                        13 (9.8)     9 (14.8)    2 (22.2)    
    Nondrinker                      383 (88.86)   245 (89.4)         121 (87.7)   17 (89.5)                               125 (88.7)                   69 (89.6)    10 (100.0)               120 (90.2)   52 (85.2)   7 (77.8)    
  Family history                                                                                              0.918                                                              0.435                                            0.404
    Yes                             25 (5.80)     21 (7.7)           3 (2.2)      1 (5.3)                                 9 (6.4)                      1 (1.3)      1 (10.0)                 12 (9.0)     2 (3.3)     0           
    No                              406 (94.20)   253 (92.3)         135 (97.8)   18 (94.7)                               132 (93.6)                   76 (98.7)    9 (90.0)                 121 (91.0)   59 (96.7)   9 (100.0)   
  WHO classification                                                                                          0.055                                                              **0.040**                                        0.435
    High-moderate differentiation   320 (83.77)   214 (85.3)         94 (81.7)    12 (75.0)                               112 (86.2)                   55 (83.3)    5 (62.5)                 102 (84.3)   39 (79.6)   7 (87.5)    
    Poor differentiation            21 (5.50)     11 (4.4)           7 (6.1)      3 (18.8)                                6 (4.6)                      3 (4.5)      2 (25.0)                 5 (4.1)      4 (8.2)     1 (12.5)    
    Mucinous adenocarcinoma         41 (10.73)    26 (10.4)          14 (12.2)    1 (6.3)                                 12 (9.2)                     8 (12.1)     1 (12.5)                 14 (11.6)    6 (12.2)    0           
  TNM stage                                                                                                   0.560                                                              0.852                                            0.291
    I--II                           174 (40.94)   109 (40.2)         56 (41.5)    9 (47.4)                                57 (41.3)                    35 (46.1)    4 (40.0)                 52 (39.1)    21 (35.6)   5 (55.6)    
    III--IV                         251 (59.06)   162 (59.8)         79 (58.5)    10 (52.6)                               81 (58.7)                    41 (53.9)    6 (60.0)                 81 (60.9)    38 (64.4)   4 (44.4)    
                                                                                                                                                                                                                                  
  rs710885                                                                                                                                                                                                                        
  Smoking                                                                                                     0.352                                                              0.457                                            0.404
    Ever smoker                     174 (40.28)   148 (40.0)         25 (43.9)    1 (20.0)                                68 (34.9)                    13 (40.6)    0                        80 (45.7)    12 (48.0)   1 (25.0)    
    Never smoker                    258 (59.72)   222 (60.0)         32 (56.1)    4 (80.0)                                127 (65.1)                   19 (59.4)    1 (100.0)                95 (54.3)    13 (52.0)   3 (75.0)    
  Drinking                                                                                                    0.510                                                              0.731                                            0.381
    Drinker                         47 (10.88)    41 (11.1)          5 (8.8)      1 (20.0)                                21 (10.8)                    3 (9.4)      0                        20 (11.4)    2 (8.0)     1 (25.0)    
    Nondrinker                      385 (89.12)   329 (88.9)         52 (91.2)    4 (80.0)                                174 (89.2)                   29 (90.6)    1 (100.0)                155 (88.6)   23 (92.0)   3 (75.0)    
  Family history                                                                                              0.156                                                              0.830                                            0.147
    Yes                             24 (5.56)     21 (5.7)           2 (3.5)      1 (20.0)                                9 (4.6)                      1 (3.1)      0                        12 (6.9)     1 (4.0)     1 (25.0)    
    No                              408 (94.44)   349 (94.3)         55 (96.5)    4 (80.0)                                186 (95.4)                   31 (96.9)    1 (100.0)                163 (93.1)   24 (96.0)   3 (75.0)    
  WHO classification                                                                                          0.682                                                              0.914                                            0.736
    High-moderate differentiation   322 (84.07)   272 (83.4)         46 (86.8)    4 (100.0)                               147 (85.0)                   25 (83.3)    1 (100.0)                125 (81.7)   21 (91.3)   3 (100.0)   
    Poor differentiation            20 (5.22)     18 (5.5)           2 (3.8)      0                                       10 (5.8)                     1 (3.3)      0                        8 (5.2)      1 (4.3)     0           
    Mucinous adenocarcinoma         41 (10.71)    36 (11.0)          5 (9.4)      0                                       16 (9.2)                     4 (13.3)     0                        20 (13.1)    1 (4.3)     0           
  TNM stage                                                                                                   0.961                                                              0.381                                            0.637
    I--II                           175 (41.08)   147 (40.4)         26 (45.6)    2 (40.0)                                83 (43.5)                    14 (43.8)    0                        64 (37.0)    12 (48.0)   2 (50.0)    
    III--IV                         251 (58.92)   217 (59.6)         31 (54.4)    3 (60.0)                                108 (56.5)                   18 (56.3)    1 (100.0)                109 (63.0)   13 (52.0)   2 (50.0)    
  rs785005                                                                                                                                                                                                                        
  Smoking                                                                                                     0.121                                                              0.208                                            0.497
    Ever smoker                     175 (40.42)   84 (42.2)          78 (41.1)    13 (29.5)                               35 (36.1)                    39 (38.2)    7 (25.0)                 49 (48.0)    39 (44.3)   6 (37.5)    
    Never smoker                    258 (59.58)   115 (57.8)         112 (58.9)   31 (70.5)                               62 (63.9)                    63 (61.8)    21 (75.0)                53 (52.0)    49 (55.7)   10 (62.5)   
  Drinking                                                                                                    0.657                                                              0.979                                            0.483
    Drinker                         385 (88.91)   21 (10.6)          23 (12.1)    4 (9.1)                                 9 (9.3)                      12 (11.8)    3 (10.7)                 12 (11.8)    11 (12.5)   1 (6.3)     
    Nondrinker                      48 (11.09)    178 (89.4)         167 (87.9)   40 (90.9)                               88 (90.7)                    90 (88.2)    25 (89.3)                90 (88.2)    77 (87.5)   15 (93.7)   
  Family history                                                                                              0.320                                                              0.122                                            0.928
    Yes                             25 (5.77)     12 (6.0)           9 (4.7)      4 (9.1)                                 3 (3.1)                      5 (4.9)      3 (10.7)                 9 (8.8)      4 (4.5)     1 (6.3)     
    No                              408 (94.23)   187 (94.0)         181 (95.3)   40 (90.9)                               94 (94.0)                    97 (95.1)    25 (89.3)                93 (91.2)    84 (95.5)   15 (93.8)   
  WHO classification                                                                                          **0.045**                                                          0.068                                            0.527
    High-moderate differentiation   322 (83.85)   141 (81.5)         142 (83.0)   39 (97.5)                               67 (78.8)                    79 (85.9)    26 (100.0)               74 (84.1)    63 (79.7)   13 (92.9)   
    Poor differentiation            20 (5.21)     13 (7.5)           7 (4.1)      0                                       9 (10.6)                     1 (1.1)      0                        4 (4.5)      6 (7.6)     0           
    Mucinous adenocarcinoma         42 (10.94)    19 (11.0)          22 (12.9)    1 (2.5)                                 9 (10.6)                     12 (13.0)    0                        10 (11.4)    10 (12.7)   1 (7.1)     
  TNM stage                                                                                                   0.992                                                              0.631                                            0.636
    I--II                           175 (40.98)   82 (42.3)          75 (39.7)    18 (40.9)                               41 (43.6)                    45 (44.6)    11 (39.3)                41 (41.0)    30 (34.1)   7 (43.8)    
    III--IV                         252 (59.02)   112 (57.7)         114 (60.3)   26 (59.1)                               53 (56.4)                    56 (55.4)    17 (60.7)                59 (59.0)    58 (65.9)   9 (56.3)    
  rs2632159                                                                                                                                                                                                                       
  Smoking                                                                                                     0.616                                                              **0.045**                                        0.526
    Ever smoker                     174 (40.37)   115 (40.9)         52 (40.0)    7 (35.0)                                51 (35.9)                    30 (39.0)    0                        64 (46.0)    22 (41.5)   7 (53.8)    
    Never smoker                    257 (59.63)   166 (59.1)         78 (60.0)    13 (65.0)                               91 (64.1)                    47 (61.0)    7 (100.0)                75 (54.0)    31 (58.5)   6 (46.2)    
  Drinking                                                                                                    0.869                                                              0.354                                            0.670
    Drinker                         48 (11.14)    31 (11.0)          15 (11.5)    2 (10.0)                                16 (11.3)                    8 (10.4)     0                        15 (10.8)    7 (13.2)    2 (15.4)    
    Nondrinker                      383 (88.86)   250 (89.0)         115 (88.5)   18 (90.0)                               126 (88.7)                   69 (89.6)    7 (100.0)                124 (89.2)   46 (86.8)   11 (84.6)   
  Family history                                                                                                                                                                 0.543                                            0.899
    Yes                             25 (5.80)     19 (6.8)           5 (3.8)      1 (5.0)                     0.875       7 (4.9)                      4 (5.2)      0                        12 (8.6)     1 (1.9)     1 (7.7)     
    No                              406 (94.20)   262 (93.2)         125 (96.2)   19 (95.0)                               135 (95.1)                   73 (94.8)    7 (100.0)                127 (91.4)   52 (98.1)   12 (92.3)   
  WHO classification                                                                                          0.991                                                              0.158                                            0.422
    High-moderate differentiation   319 (83.51)   215 (84.3)         90 (81.8)    14 (82.4)                               111 (86.0)                   55 (82.1)    4 (66.7)                 104 (82.5)   35 (81.4)   10 (90.9)   
    Poor differentiation            21 (5.50)     15 (5.9)           5 (4.5)      1 (5.9)                                 8 (6.2)                      3 (4.5)      0                        7 (5.6)      2 (4.7)     1 (9.1)     
    Mucinous adenocarcinoma         42 (10.99)    25 (9.8)           15 (13.6)    2 (11.8)                                10 (7.8)                     9 (13.4)     2 (33.3)                 15 (11.9)    6 (14.0)    0           
  TNM stage                                                                                                   0.183                                                              0.436                                            0.237
    I--II                           173 (40.71)   106 (38.0)         56 (44.4)    11 (55.0)                               56 (40.0)                    35 (46.7)    4 (57.1)                 50 (36.0)    21 (41.2)   7 (53.8)    
    III--IV                         252 (59.29)   173 (62.0)         70 (55.6)    9 (45.0)                                84 (60.0)                    40 (53.3)    3 (42.9)                 89 (64.0)    30 (58.8)   6 (46.2)    

Terms in bold represent significant results (*P*\<0.05). The *P* value was calculated using the recessive model.^\*^, using χ^2^ two-side test.

eQTL analysis {#sec3-6}
-------------

In the HaploReg database, the promising SNP rs2632159 was found to potentially change the site of binding with EBF, LUN-1, and TCF12, which are transcription factors \[[@B18]\] ([Figure 1](#F1){ref-type="fig"}).

![The bioinformatical analysis for rs2632159 SNP\
In the HaploReg database, the promising SNP rs2632159 was found possibly to change the combination site with the following proteins with the certain polypeptide.](bsr-39-bsr20190708-g1){#F1}

Discussion {#sec4}
==========

To date, no study has reported on the association of *PCAT1* polymorphisms and CRC risk. We thus screened all tagSNPs for the *PCAT1* gene and investigated whether these SNPs could be biomarkers for CRC risk. We reported for the first time that *PCAT1* rs2632159 polymorphism could increase the risk of CRC. We then performed an eQTL analysis and found that rs2632159 polymorphism could alter the site of binding with three different transcription factors, which may explain why rs2632159 polymorphism increased CRC risk. Our study should be helpful in the search for promising biomarkers for the prediction of CRC at an early stage.

These five tagSNPs represented all of the SNPs covering the *PCAT1* gene. In terms of the locations, rs1902432 and rs4573233 polymorphisms are intronic and in the region 2 kb upstream of the gene, respectively; rs710885 and rs785005 are intronic; and rs2632159 is 145 bp downstream of the gene. Thus far, no study has reported the association of *PCAT1* polymorphisms and CRC risk. Only the *PCAT1* rs1902432 SNP was reported to be significantly associated with other cancer, namely, increasing the risk of prostate cancer \[[@B7]\]. In our study, we found that the rs1902432 SNP was associated with colon cancer risk, but not with disease risk in all CRC patients. Thus, rs1902432 SNP may only have potential to be a biomarker for colon cancer risk.

The major finding in the present study was that the *PCAT1* rs2632159 SNP increased CRC susceptibility, and functioned as a risk factor for colon cancer under the dominant model and for rectal cancer under the recessive model. This SNP was thus reported to be related to disease risk for the first time. The explanation for this phenomenon should be considered from two aspects: first, the etiology of colon cancer and rectal cancer is different. The etiology of colon cancer is often related to genetic factors. Its precancerous disease may be familial polyposis, and its patients often have microsatellite instability, for example, MLH1, MSH2, MSH6 and PMS2 deficiency. While the etiology of rectal cancer is often related to the unhealthy dietary habit, and patients often have poor defecation habits, resulting in a large number of toxins accumulated in the rectum, resulting in repeated irritation of rectal mucosa by inflammation, thus resulting the occurrence of colon cancer. Second, the basis of genetics varies from the dominant model and recessive model. The dominant model is a single variation for the allele of one polymorphism, while the recessive model needs to achieve double variation for two alleles of one polymorphism. This is similar to the 'two-hit hypothesis' \[[@B19]\] in genetics.

*PCAT1* rs2632159 SNP was also found to have a more pronounced effect in the male subgroup. This SNP was also shown to have epistatic effects with other polymorphisms. Epistasis is a phenomenon in which the effects of complex interactions are more important than the independent main effects of any one susceptibility gene \[[@B20]\]. When rs2632159 polymorphism is present, the rs1902432 TT+TC variant genotype was shown to increase the risk of rectal cancer, and the rs785005 GG variant genotype increased the risk of colon cancer; this suggests the potential for pairwise effects of SNP--SNP interaction in the *PCAT1* gene. Finally, eQTL analysis using an online bioinformatic tool was performed for this promising rs2632159 polymorphism, and EBF, LUN-1, and TCF12 were found to probably combine with the rs2632159 T\>C variant. Then, this rs2632159 T\>C variant would cause a gain or loss function for these transcription factors. PCAT1 is a lncRNA that functions as an oncogene \[[@B23]\]. We thus speculate that these three transcription factors could stimulate PCAT1 transcription and increase the level of oncogene functional PCAT1 expression, causing individuals carrying the variant genotype to express more oncogenic PCAT1 and therefore increase the risk of CRC.

Gene research may be related to race and this will limit some application of the SNP for the different ethnicity. For example, our research found that *PCAT1* rs2632159 SNP was shown to increase CRC susceptibility in a Chinese population, and the rs1902432 SNP might only have potential to be a biomarker for colon cancer risk in the Chinese population. While the *PCAT1* rs1902432 SNP was also reported to be significantly associated with the risk of prostate cancer in Chinese population \[[@B7]\]. In [Figure 2](#F2){ref-type="fig"}, we listed the Hapmap data for the *PCAT1* rs2632159 and rs1902432 SNPs, which showed rs2632159 varied from Europeans to Asians to Africans (the T allele percentage, 30% in Europeans, 80% in Asians, 10% in Africans), so was the rs1902432 SNP. Thus, the application of *PCAT1* rs2632159 and rs1902432 SNPs for cancer risk might be considered from race to race.

![The genotype information from Hapmap database\
The genotype for *PCAT1* rs2632159 and rs1902432 SNPs from the Hapmap database (<https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?do_not_redirect&rs=rs2632263>; <https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?do_not_redirect&rs=rs1902432.)>](bsr-39-bsr20190708-g2){#F2}

It was reported that the combined haplotype analyses for multiple SNPs are more sensitive and powerful than single-locus SNP analysis alone \[[@B29]\]. The single-locus SNP rs4573233, rs710885 and rs785005 SNPs alone had no significant association with colon risk, but when these three SNPs composed a combination with others (rs1902432 and rs2632159), we found that the *PCAT1* C G T G T haplotype of rs1902432 -- rs4573233 -rs710885 -- rs785005 -- rs2632159 SNPs significantly decreased the colon risk (OR = 0.75), indicating that the haplotype might be more sensitive than these three single SNP its own, and could also have potential for the prediction of colon cancer risk.

There are some limitations in the present study. First, the sample size could be increased to obtain more reliable results, but the total sample size of nearly 1000 is reasonable. Second, the prognostic data could have been studied to achieve a more comprehensive analysis, but the survival rate of CRC was high, which limited the predictive role of the SNP for CRC prognosis. Third, whether the *PCAT1* rs2632159 associated with other gastrointestinal cancers were not studied in this research, which would determine the application and specificity of the *PCAT1* polymorphisms.

In summary, in the present study, the *PCAT1* rs2632159 SNP was shown to increase CRC susceptibility, and it was shown to increase the risk of colon cancer under the dominant model and of rectal cancer under the recessive model. In the subgroup analysis, the *PCAT1* rs2632159 SNP also increased the risk of rectal cancer in males. And the rs1902432 SNP might only have potential to be a biomarker for colon cancer risk. These findings should help in the search for biomarkers predictive of CRC susceptibility and provide more clues to obtain a deeper understanding of the etiology of colorectal carcinogenesis.

Supporting information {#sec5}
======================


###### The captured SNPs covered by the selected tagSNPs

###### The baseline of the subjects

Funding {#sec6}
=======

This work is supported partly by the Natural Science Foundation of Liaoning Province in China \[grant number 20170541001\]. We thank Liwen Bianji, Edanz Group China ([www.liwenbianji.cn/ac](https://www.liwenbianji.cn/ac)), for editing the English text of a draft of this manuscript.

Competing Interests {#sec7}
===================

The authors declare that there are no competing interests associated with the manuscript.

Author Contribution {#sec8}
===================

Ben-gang Wang conceived and designed the present study. Ming-li Yang, Zhe Huang, Li-na Wu preformed the experiment. Han-xi Ding was responsible for the data analysis and performed data interpretation. Ming-li Yang wrote the paper. Rong Wu and Ben-gang Wang revised the manuscript.

CI

:   confidence interval

CON

:   controls

CRC

:   colorectal cancer

eQTL

:   quantitative trait locus

LD

:   linkage disequilibrium

OR

:   odds ratio

PCAT

:   prostate cancer-associated transcript

SNP

:   single nucleotide polymorphism
